EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Intra‐Arterial Alteplase After Successful Endovascular Reperfusion in Patients Without Intravenous Thrombolysis: A Subgroup Analysis of the PEARL Randomized Clinical Trial

Dongshu Xie iD, Haiwei Li, Dengxing Li, Weidong Huang, Xuejing Lin, Zhenhong Deng iD, Xi Chen iD, Xinguang Yang, Yongteng Xu iD, Songhua Xiao, Jiyun Feng iD, Yamei Tang iD und 1 weitere

Journal of the American Heart Association · 03.11.2026 · 15 (21)

DOI: 10.1161/jaha.126.049961 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 03.11.2026. Verfasst von Dongshu Xie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou China. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Fibrinolytic Agents, Endovascular Procedures, Thrombectomy. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For patients with large‐vessel occlusion stroke who undergo endovascular thrombectomy without prior intravenous thrombolysis, the efficacy and safety of adjunctive intra‐arterial alteplase (IAA) after successful endovascular reperfusion remain uncertain.

Methods

This was a prespecified subgroup analysis of the PEARL (Intra‐Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke) randomized clinical trial conducted at 28 centers in China, focusing on patients who underwent endovascular thrombectomy without prior intravenous thrombolysis. Patients were stratified by treatment assignment: IAA treatment versus standard treatment (control). The primary efficacy outcome was the proportion of patients achieving excellent functional outcome, defined as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage, any intracranial hemorrhage within 36 hours, and 90‐day all‐cause mortality.

Results

Among 324 patients originally randomized in the PEARL trial, 189 underwent endovascular thrombectomy without prior intravenous thrombolysis and were included in this analysis. Of the 189 patients, 95 were assigned to the IAA treatment group and 94 to the standard treatment group. Excellent functional outcome at 90 days was significantly higher in the IAA treatment group compared with the standard treatment group (43.2% [41/95] versus 22.6% [21/93]; adjusted risk ratio [aRR], 1.86; 95% CI, 1.19–2.91; P= 0.007). The absolute risk reduction was 20.6% (95% CI, 7.0%–33.1%). Results were consistent in per‐protocol sensitivity analyses ( P= 0.002). No significant differences were observed in symptomatic intracranial hemorrhage (aRR, 0.93; 95% CI, 0.28–3.13; P= 0.908), any intracranial hemorrhage (aRR, 1.04; 95% CI, 0.68–1.60; P= 0.843), or 90‐day mortality (hazard ratio [HR], 1.00; 95% CI, 0.49–2.04; P >0.99).

Conclusions

In patients who did not receive prior intravenous thrombolysis, adjunctive IAA after successful endovascular thrombectomy was associated with a higher likelihood of excellent functional outcome at 90 days, without an apparent increase in symptomatic intracranial hemorrhage or mortality. Registration URL: clinicaltrials.gov ; Unique Identifier: NCT05856851.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Plasminogen ActivatorFibrinolytic AgentsEndovascular ProceduresThrombectomyIschemic StrokeHumansFemaleMaleAgedTreatment OutcomeMiddle AgedThrombolytic TherapyTime FactorsChinaInfusions, Intra-ArterialIntracranial Hemorrhages

Stichwörter der Autor:innen

endovascular thrombectomyintra‐arterial alteplaselarge vessel occlusionsubgroup analysis

Substanzen

Tissue Plasminogen ActivatorFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Neurology Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou China.
  • Department of Neurology Baise People's Hospital Baise China.
  • Department of Neurology Xinhui People's Hospital Jiangmen China.
  • Department of Neurology Lianzhou People's Hospital Lianzhou China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou China.
  • Guangdong Province Key Laboratory of Brain Function and Disease Zhongshan School of Medicine, Sun Yat-Sen University Guangzhou China.

ORCID-Profile: Dongshu Xie, Zhenhong Deng, Xi Chen, Yongteng Xu, Jiyun Feng, Yamei Tang, Xiaoming Rong

Zitieren

APA

Xie, D., Li, H., Li, D., Huang, W., Lin, X., Deng, Z., Chen, X., Yang, X., Xu, Y., Xiao, S., Feng, J., Tang, Y., & Rong, X. (2026). Intra‐Arterial Alteplase After Successful Endovascular Reperfusion in Patients Without Intravenous Thrombolysis: A Subgroup Analysis of the PEARL Randomized Clinical Trial. Journal of the American Heart Association, 15(21). https://doi.org/10.1161/jaha.126.049961

Vancouver

Xie D, Li H, Li D, Huang W, Lin X, Deng Z, et al. Intra‐Arterial Alteplase After Successful Endovascular Reperfusion in Patients Without Intravenous Thrombolysis: A Subgroup Analysis of the PEARL Randomized Clinical Trial. Journal of the American Heart Association. 2026;15(21). doi:10.1161/jaha.126.049961

BibTeX
@article{Xie2026,
  author = {Xie, Dongshu and Li, Haiwei and Li, Dengxing and Huang, Weidong and Lin, Xuejing and Deng, Zhenhong and Chen, Xi and Yang, Xinguang and Xu, Yongteng and Xiao, Songhua and Feng, Jiyun and Tang, Yamei and Rong, Xiaoming},
  title = {Intra‐Arterial Alteplase After Successful Endovascular Reperfusion in Patients Without Intravenous Thrombolysis: A Subgroup Analysis of the PEARL Randomized Clinical Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {21},
  doi = {10.1161/jaha.126.049961}
}
Kostenlos starten →